Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 29:15:30588.
doi: 10.34172/bi.30588. eCollection 2025.

Thalidomide augments maturation and T helper 1-inducing capacity of monocyte-derived dendritic cells in vitro

Mohsen Abbaszadeh  1 , Bahar Naseri  2 , Javad Masoumi  2 , Elham Baghbani  2 , Behzad Baradaran  2   3 , Mohammad Reza Sadeghi  1
Affiliations

Thalidomide augments maturation and T helper 1-inducing capacity of monocyte-derived dendritic cells in vitro

Mohsen Abbaszadeh et al. Bioimpacts. .

Abstract

Introduction: Dendritic cells (DCs) possess specialized abilities to present antigens and stimulate T cells, making them essential in triggering adaptive immune responses. Thalidomide and its derivatives are classified as a group of medications that possess immunomodulatory properties. Numerous studies have demonstrated the contentious impact of these drugs on DCs. Therefore, the objective of the present study was to assess the influence of Thalidomide therapy on the maturation and stimulation of monocyte-derived DCs, and subsequently examine the consequences of these treated DCs on the immune responses of autologous T cells.

Methods: The immature DCs derived from monocytes were subjected to exposure to Thalidomide and Lipopolysaccharides (LPS) on the fifth day of differentiation, followed by a 24-hour incubation period. On the sixth day, the phenotypic features of the DCs in both the control and treatment groups were assessed using flow cytometry. Subsequently, the gene expression in both the DCs and autologous T cells co-cultured with the DCs was evaluated using the real-time PCR method.

Results: Thalidomide-treated DCs exhibited a significant augmentation in the expression of maturation and stimulatory surface markers CD11c, HLA-DR, and CD86 (P ≤ 0.01), as well as gene expression of TNF-α and IL-12 (P ≤ 0.01) when compared to the control group. Furthermore, co-culture of Thalidomide-treated DCs with T cells increased T-bet and IFN-γ (P ≤ 0.01) expression, while diminished FOXP3 and TGF-β (P ≤ 0.01) expression compared to T cells co-cultured with untreated DCs.

Conclusion: Our findings indicate that in vitro Thalidomide treatment shifts DCs towards an immunogenic state and elevates their T helper 1 inducing capacity, which may be efficient in immunotherapy of various cancers.

Keywords: Cancer; Immunomodulation; Monocyte-derived dendritic cell; T cell; Thalidomide.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Fig. 2
Fig. 2
Fig. 3
Fig. 3
Fig. 4
Fig. 4
Fig. 5
Fig. 5
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Friedrich M, Hahn M, Michel J, Sankowski R, Kilian M, Kehl N, et al. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. Neuro Oncol. 2023;25:263–76. doi: 10.1093/neuonc/noac138. - DOI - PMC - PubMed
    1. Sohrabi S, Masoumi J, Naseri B, Ghorbaninezhad F, Alipour S, Kazemi T, et al. STATs signaling pathways in dendritic cells: as potential therapeutic targets? Int Rev Immunol. 2024;43:138–59. doi: 10.1080/08830185.2023.2274576. - DOI - PubMed
    1. Fu C, Ma T, Zhou L, Mi QS, Jiang A. Dendritic cell-based vaccines against cancer: challenges, advances and future opportunities. Immunol Invest. 2022;51:2133–58. doi: 10.1080/08820139.2022.2109486. - DOI - PubMed
    1. Masoumi J, Zainodini N, Basirjafar P, Tavakoli T, Zandvakili R, Nemati M, et al. Apelin receptor antagonist boosts dendritic cell vaccine efficacy in controlling angiogenic, metastatic and apoptotic-related factors in 4T1 breast tumor-bearing mice. Med Oncol. 2023;40:179. doi: 10.1007/s12032-023-02030-9. - DOI - PubMed
    1. Ghorbaninezhad F, Masoumi J, Bakhshivand M, Baghbanzadeh A, Mokhtarzadeh A, Kazemi T, et al. CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro. Front Immunol. 2022;13:931316. doi: 10.3389/fimmu.2022.931316. - DOI - PMC - PubMed

LinkOut - more resources